DCR

multiple myeloma - 2nd line (L2) multiple myeloma - 2nd line (L2)

versus pomalidomide and dexamethasone
pembrolizumab plus pomalidomide and dexamethasone vs. pomalidomide and dexamethasone 1 certainty unassessable+1%